Drugs / imaradenant
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04478513 | Jul → Dec 2020 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03980821 | Jul 2019 → Sep 2020 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03710434 | Nov 2018 → Apr 2019 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02740985 | Jun 2016 → Dec 2020 | castration-resistant prostate carcinoma, colorectal carcinoma, high grade malignant neoplasm, non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03381274 | May 2018 → May 2021 overdue | non-small cell lung carcinoma | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04495179 | Aug 2020 → Nov 2021 | castration-resistant prostate carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT04089553 | Aug 2019 → Jun 2021 | castration-resistant prostate carcinoma | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2019-03-14 | AstraZeneca | Results AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting astrazeneca.com ↗
Early clinical activity has been observed with AZD4635 monotherapy or in combination with Imfinzi in patients with metastatic castration-resistant prostate cancer (Abstracts #LB-192/10, #CT026/21) |
| 2018-04-18 | Nxera Pharma UK Limited | Results New data demonstrating AZD4635,a novel A2A receptor antagonist,induces anti-tumor immunity alone & in combination with anti-PD-L1 in preclinical model nxera.life ↗
Treatment with AZD4635 alone and in combination with an anti -PD-L1 antibody led to a significant reduction in tumou r growth in syngeneic tumour models exhibiting both high and low levels of adenosine |
| 2018-02-08 | Nxera Pharma UK Limited | Results Other nxera.life ↗
新規選択的アデノシンA2A 受容体拮抗薬の第I 相臨床試験において主要評価項目をほぼ達成 |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-11-12 | Nxera Pharma UK Limited | Sosei Heptares Notes that its Partnered Adenosine A2a Antagonist Imaradenant (AZD4635) has been Removed from AstraZeneca’s Clinical Pipeline nxera.life ↗ |
| 2019-03-14 | AstraZeneca | AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting astrazeneca.com ↗ |
| 2018-05-16 | Nxera Pharma UK Limited | “Optimism for A2a” - Sosei’s AZD4635 covered in BioCentury nxera.life ↗ |
| 2018-04-18 | Nxera Pharma UK Limited | New data demonstrating AZD4635,a novel A2A receptor antagonist,induces anti-tumor immunity alone & in combination with anti-PD-L1 in preclinical model nxera.life ↗ |
| 2018-02-08 | Nxera Pharma UK Limited | Other nxera.life ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | imaradenant | “Imaradenant is a novel potent and selective adenosine A2A receptor antagonist that is hypothesized to reduce immune suppression in the tumor microenvironment.” PMID 38086998 ↗ Dec 2023 |
| Known as | AZD-4635 (HTL1071) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594442 ↗ |
| Known as | AZD4635 | “Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study.” PMID 38086998 ↗ Dec 2023 |
| Known as | HTL-1071 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594442 ↗ |
| Known as | IMARADENANT (AZD4635) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594442 ↗ |
| Action | Inhibit | “Adenosine A2a receptor antagonist” CHEMBL4594442 ↗ |
| Modality | Small molecule | — CHEMBL4594442 ↗ |
| Route | Oral | “AZD4635 will be administered orally as a nanosuspension or capsule” NCT02740985 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor antagonist” CHEMBL4594442 ↗ |